Oruka Therapeutics Reports Positive Interim Data From Phase 1 Study Of ORKA-001
(RTTNews) - Oruka Therapeutics, Inc. (ORKA) Tuesday announced positive interim data from its Phase 1 study evaluating the safety and pharmacokinetics of ORKA-001 in healthy volunteers.
ORKA-001, a long-acting monoclonal antibody targeting IL-23p19, is being investigated for the treatment of patients with Psoriasis.
In the Phase 1 study, ORKA-001 demonstrated an estimated half-life of about 100 days, suggesting the potential for once-yearly dosing, and was well tolerated with a favorable safety profile.
Initial data from the ongoing EVERLAST-A Phase 2a study are expected in the second half of 2026. Oruka also expects to initiate a Phase 2b study of ORKA-001 in patients with plaque psoriasis, dubbed EVERLAST-B, in the first half of 2026.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.